Trending NewsTrending NewsNASDAQ:IRMD iRadimed (IRMD) Stock Price, News & Analysis $66.17 +7.83 (+13.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$66.05 -0.12 (-0.18%) As of 08/1/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About iRadimed Stock (NASDAQ:IRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iRadimed alerts:Sign Up Key Stats Today's Range$59.00▼$66.5050-Day Range$51.09▼$66.1752-Week Range$42.34▼$66.50Volume108,444 shsAverage Volume40,089 shsMarket Capitalization$841.68 millionP/E Ratio42.69Dividend Yield1.03%Price Target$72.00Consensus RatingBuy Company Overview IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL. Read More iRadimed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreIRMD MarketRank™: iRadimed scored higher than 84% of companies evaluated by MarketBeat, and ranked 146th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingiRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageiRadimed has received no research coverage in the past 90 days.Read more about iRadimed's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth20.48% Earnings GrowthEarnings for iRadimed are expected to grow by 20.48% in the coming year, from $1.66 to $2.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iRadimed is 42.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.11.Price to Earnings Ratio vs. SectorThe P/E ratio of iRadimed is 42.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.89.Price to Book Value per Share RatioiRadimed has a P/B Ratio of 9.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.84% of the float of iRadimed has been sold short.Short Interest Ratio / Days to CoveriRadimed has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in iRadimed has recently decreased by 1.60%, indicating that investor sentiment is improving. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldiRadimed pays a meaningful dividend of 1.17%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthiRadimed has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of iRadimed is 43.87%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, iRadimed will have a dividend payout ratio of 34.00% next year. This indicates that iRadimed will be able to sustain or increase its dividend.Read more about iRadimed's dividend. Sustainability and ESG4.4 / 5Environmental Score-0.85 Percentage of Shares Shorted2.84% of the float of iRadimed has been sold short.Short Interest Ratio / Days to CoveriRadimed has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in iRadimed has recently decreased by 1.60%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.50 News SentimentiRadimed has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for iRadimed this week, compared to 3 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, iRadimed insiders have not sold or bought any company stock.Percentage Held by Insiders36.80% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iRadimed's insider trading history. Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iRadimed and its competitors with MarketBeat's FREE daily newsletter. Email Address IRMD Stock News HeadlinesWhat To Expect From iRadimed Corp (IRMD) Q2 2025 EarningsAugust 2 at 9:25 AM | finance.yahoo.com6IRMD : Earnings Preview: iRadimedAugust 2 at 9:25 AM | benzinga.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.August 2 at 2:00 AM | Timothy Sykes (Ad)IRadimed Corporation (NASDAQ:IRMD) Q2 2025 Earnings Call TranscriptAugust 2 at 9:25 AM | msn.comIradimed (IRMD) Q2 Revenue Jumps 14%August 2 at 2:54 AM | fool.comIRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call TranscriptAugust 1 at 1:14 PM | seekingalpha.comIRADIMED CORPORATION Reports Record Second Quarter 2025 Financial ResultsAugust 1 at 8:30 AM | globenewswire.comIRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025July 25, 2025 | globenewswire.comSee More Headlines IRMD Stock Analysis - Frequently Asked Questions How have IRMD shares performed this year? iRadimed's stock was trading at $55.00 at the beginning of 2025. Since then, IRMD shares have increased by 20.3% and is now trading at $66.17. How were iRadimed's earnings last quarter? iRadimed Corporation (NASDAQ:IRMD) released its quarterly earnings results on Thursday, February, 13th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by $0.05. The medical equipment provider earned $19.39 million during the quarter, compared to the consensus estimate of $19.09 million. iRadimed had a net margin of 26.33% and a trailing twelve-month return on equity of 23.28%. Read the conference call transcript. Who are iRadimed's major shareholders? iRadimed's top institutional investors include Copeland Capital Management LLC (3.60%), Envestnet Asset Management Inc. (0.53%), Shaker Investments LLC OH (0.42%) and Teacher Retirement System of Texas (0.32%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto and John Glenn. View institutional ownership trends. How do I buy shares of iRadimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iRadimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that iRadimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG). Company Calendar Last Earnings2/13/2025Record date for 5/30 Dividend5/20/2025Ex-Dividend for 5/30 Dividend5/20/2025Dividend Payable5/30/2025Today8/02/2025Record date for 8/28 Dividend8/18/2025Dividend Payable8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:IRMD CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees110Year FoundedN/APrice Target and Rating Average Price Target for iRadimed$72.00 High Price Target$72.00 Low Price Target$72.00 Potential Upside/Downside+8.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$1.55 Trailing P/E Ratio42.69 Forward P/E Ratio39.86 P/E GrowthN/ANet Income$19.23 million Net Margins26.33% Pretax Margin33.23% Return on Equity23.28% Return on Assets20.59% Debt Debt-to-Equity RatioN/A Current Ratio8.87 Quick Ratio7.62 Sales & Book Value Annual Sales$73.24 million Price / Sales11.49 Cash Flow$1.79 per share Price / Cash Flow36.87 Book Value$6.85 per share Price / Book9.66Miscellaneous Outstanding Shares12,720,000Free Float8,036,000Market Cap$841.68 million OptionableOptionable Beta0.94 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:IRMD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRadimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share iRadimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.